Akzo Nobel says it is "gradually returning to growth" after sum of two units years during which sales declined.

Akzo Nobel says it is "gradually returning to growth" after sum of two units years during which sales declined, mainly becoming to expiry of the patent for Remeron the company's top-selling antidepressant medicine Speaking at an analysts' presentation in London last week, CEO Hans Wijers said Akzo is well in succession its way to achieving a previously announced goal of "fixing pharma," and to expanding significantly the company's coatings business, which is the leader in that market. Chemicals, the third pillar of Akzo's portfolio, have undergone a major restructuring and divestment program in the past year, and are "performing above the require to be paid [i]or[/i] undergone of ...

Want to read the whole article? You can purchase it here. It's quick and easy....